Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Annals of HematologyOpen Access

Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPisanupong TechaapornkunWRWaranyoo RojpalakornNMNuthchaya Mejun

Discussion

Loading...

Member takes

Overview

Meta-analysis compares efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma, indicating significant differences in response rates.

Key Points

  • CAR-T therapies showed an overall response rate of 84%, which is significantly higher than the 65% observed for BiTEs.
  • Meta-regression confirmed that CAR-T significantly outperformed BiTEs in efficacy, despite higher associated toxicity.
  • Dual-targeted CAR-T therapies, such as anti-BCMA paired with anti-CD38/CD19, yielded the highest efficacy rates of 92%.
  • While CAR-T therapies provided deeper responses, they were also linked to greater toxicity, suggesting the need for personalized treatment options.

Cite This Study

Techaapornkun et al. (2025) studied this question.

synapsesocial.com/papers/68d413ee713b0b5dfea619aehttps://doi.org/10.1007/s00277-025-06524-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  2. 2Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  3. 3Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025
  4. 4CD38BiTE-secretion overcomes antigen escape in BCMA-targeted CAR T cell therapy for multiple myeloma2025
  5. 5Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations